Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$118.71
pos +0.00
+0.00%
Today's Range: 115.27 - 120.72 | CELG Avg Daily Volume: 5,419,400
Last Update: 04/24/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 3.78%
Open: $0.00
Previous Close: $116.09
52 Week Range: $69.88 - $129.06
Oustanding Shares: 800,590,656
Market Cap: 92,940,569,255
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 14 15 14
Moderate Buy 1 1 1 1
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.47 1.45 1.47
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 48.57
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
48.57 48.50 28.22
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.30% 63.94% 199.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.93 $1.05 $4.42 $6.19
Number of Analysts 4 4 4 4
High Estimate $1.01 $1.12 $4.73 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.42
Growth Rate (Year over Year) 27.05% 31.25% 31.62% 39.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Rigs Reduction Real Money Pro($)

The market is about at the same levels as it was during my last update an hour and a half go. Baker Hughes' (BHI) latest survey shows domestic rigs falling for the 20th consecutive week, bringing the total number of active rigs down to 703 from their October peak of about 1,600. Now that is a major adjustment in a relatively short period of time. How many jobs got whacked as a result is a question I would like to know the answer to.
Biogen miss no reason to abandon big 4 of Big Pharma.
Even the second-tier biotechs are taking off.
The weak dollar was the breeze that pushed the market higher.
Three stocks were ripe for buying after the pullback.
An answer to those asking me what's worth buying.
If there is no catalyst, I'd join those who sell on a bounce.
It takes a village of positive reports to sustain market.
Where are Celgene, Isis and CVS heading?
Here are healthcare stocks of all shares and sizes with strong charts.

Columnist Conversations

A Kinder Morgan (KMI) director unloaded 1 MM shares for $43.696 MM last week (on Apr. 20 + 21)
CMG's CEO sold 12,000 shares at $690 - $695 for a total on $8.021 MM on April 21, 2015. CMG's CFO sold 9,000 s...
Technical analysis is, in large measure, about finding repetitive price patterns and sometimes the inverse of ...
As a student of retail, I tell you this: it's weird to not see the Apple Watch in the top Best Buy and Macy's ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.